|
|
|
|
|
|
|
|
| James Wikel, CTO, Coalesix |
|
| James Wikel is currently the Chief Technology Officer of Coalesix Inc. founded in late 2004 in Cambridge MA. He retired from Eli Lilly & Company in 2004 as head of the Department of Structural and Computational Sciences, Discovery Chemistry Research and Technologies Division of Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana. He joined Lilly in 1971 as an organic chemist and moved into the emerging computational chemistry area in 1989 as a member of that department created to maximize the corporate investment in a Cray-2 Supercomputer. He has been actively engaged in pharmaceutical research for over 33 years as both a laboratory scientist and as a scientific manager and has 34 peer-reviewed scientific publications and 47 issued U.S. Patents. The subject matter included in these patents and publications describe 3 molecules that underwent clinical evaluation as drug candidates, enviroxime, enviradene, and frentizole, and one successfully marketed agricultural product, BEAM. As a computational chemistry scientist, he has published in a broad range of topics with expertise in QSAR studies and algorithm development. He established the QSAR group at Lilly and initiated the development of proprietary predictive methods. He led a group of information technologists, computer scientists, and computational chemistry scientists from within the global Lilly Research Labs scientific community and in partnership with external collaborators to deliver computational methods across the organization via a web based integration framework application.
|
|
|
|
An Interactive Environment for Knowledge Management
James H Wikel, Coalesix Inc., Cambridge, MA, USA
The challenge of developing useful drugs from active molecules is a daunting problem. It is a complex task requiring the simultaneous satisfaction of many criteria including: inherent potency, low side effect profile, good solubility, oral absorption, appropriate distribution in various tissues including the target tissue, metabolism at a rate that ensures sufficient residence time in vivo to be an effective drug, and excretion of parent drug and metabolites in order to minimize any toxic accumulation. The pharmaceutical industry has collected data in these areas for decades. In some cases, the analysis of these data has provided sufficient information to overcome a challenge with one or more of these criteria. The evaluation of these important properties generally occurs after potency is nearly maximized and then only the most potent compounds in the SAR are subjected to these studies. Effective knowledge management from these multidimensional data combined with the expert intuition of the scientist is a challenge for the industry in order to increase the efficiency of drug discovery. We have developed a novel optimization technology focused on providing an in silico environment enabling and synergizing multiparameter optimization with expert intuition and knowledge. The resulting environment enables the identification of a diverse selection of preclinical drug candidate molecules with better overall properties, thus supporting better decision making and providing a higher likelihood of clinical success.
Several components of the knowledge management problem - such as synthetic tractability or IP status - are subjective or inherently implicit and so do not lend themselves to a purely computational approach. Coalesix's Candidate Design Environment is based on Interactive Evolutionary Computing (IEC). IEC is an optimization technique, which uses subjective human evaluation in problems where it is difficult or impossible to design a fitness function for automatic search of the input space.
|
|
|
|
|
|
|
